Furthermore, several clinic trials such as VISION trial (14), TheraP trial (15), and LuPSMA trial (16) have demonstrated promising results of PSMA-targeted therapy in PCa patients. This evidence concerns the gene FOLH1 and posterior cortical atrophy.